Free Trial

CG Oncology (CGON) Stock Price, News & Analysis

CG Oncology logo
$25.98 -0.58 (-2.18%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CG Oncology Stock (NASDAQ:CGON)

Key Stats

Today's Range
$25.48
$28.06
50-Day Range
$15.59
$29.05
52-Week Range
$14.80
$40.47
Volume
771,395 shs
Average Volume
827,388 shs
Market Capitalization
$1.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.22
Consensus Rating
Buy

Company Overview

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

CG Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

CGON MarketRank™: 

CG Oncology scored higher than 45% of companies evaluated by MarketBeat, and ranked 597th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CG Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CG Oncology is -17.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CG Oncology is -17.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    24.37% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 23.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CG Oncology does not currently pay a dividend.

  • Dividend Growth

    CG Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.37% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 23.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CG Oncology has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for CG Oncology this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for CGON on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,760.00 in company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of CG Oncology is held by insiders.

  • Percentage Held by Institutions

    Only 26.56% of the stock of CG Oncology is held by institutions.

  • Read more about CG Oncology's insider trading history.
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGON Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Q2 Earnings Estimate for CG Oncology Issued By HC Wainwright
See More Headlines

CGON Stock Analysis - Frequently Asked Questions

CG Oncology's stock was trading at $28.68 at the start of the year. Since then, CGON shares have decreased by 5.4% and is now trading at $27.14.
View the best growth stocks for 2025 here
.

CG Oncology, Inc. (NASDAQ:CGON) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The company earned $0.05 million during the quarter, compared to the consensus estimate of $0.53 million. CG Oncology had a negative net margin of 10,642.98% and a negative trailing twelve-month return on equity of 18.97%.

CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at a price of $19.00 per share.

Top institutional shareholders of CG Oncology include Vanguard Group Inc. (7.66%), Wellington Management Group LLP (2.79%), Alliancebernstein L.P. (2.47%) and Goldman Sachs Group Inc. (1.01%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post.
View institutional ownership trends
.

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
5/13/2025
Today
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.22
High Stock Price Target
$75.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+127.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-48,610,000.00
Net Margins
-10,642.98%
Pretax Margin
-10,642.98%

Debt

Sales & Book Value

Annual Sales
$662,000.00
Price / Cash Flow
N/A
Book Value
($1.94) per share
Price / Book
-13.22

Miscellaneous

Free Float
N/A
Market Cap
$1.96 billion
Optionable
Optionable
Beta
1.08
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:CGON) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners